| Unknown | Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam NCT05506475 | Institut Pasteur | — |
| Unknown | Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment o NCT05601518 | Beijing Tsinghua Chang Gung Hospital | — |
| Completed | Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection NCT04042740 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Phase 2 |
| Unknown | Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam NCT03601546 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks NCT03122132 | Hepa C | — |
| Completed | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma NCT02940496 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Hepatitis C Infection in World Trade Center Responders NCT02982993 | Icahn School of Medicine at Mount Sinai | — |
| Active Not Recruiting | DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection NCT02772003 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genot NCT02582632 | AbbVie | Phase 3 |
| Completed | A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals NCT02568332 | University of Oxford | Phase 1 |
| Completed | Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related NCT02427204 | Icahn School of Medicine at Mount Sinai | — |
| Terminated | Effects of Persistent Innate Immune Activation on Vaccine Efficacy NCT02429583 | Rockefeller University | Phase 4 |
| Completed | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors NCT02143401 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Safety Study of the Aethlon Hemopurifier NCT02215902 | Aethlon Medical Inc. | N/A |
| Completed | A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir NCT02323594 | Bristol-Myers Squibb | Phase 1 |
| Completed | Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype NCT02247401 | AbbVie | Phase 3 |
| Completed | A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination NCT02362217 | University of Oxford | Phase 1 |
| Completed | HCV-HIV Co-infected Patient Cohort in Thailand NCT02247440 | Institut de Recherche pour le Developpement | Phase 4 |
| Completed | Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Re NCT02220868 | Saint Michael's Medical Center | Phase 4 |
| Completed | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Parti NCT02105701 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of Drug Combination on Pharmacokinetics in Healthy Volunteers NCT02175602 | Bristol-Myers Squibb | Phase 1 |
| Completed | Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infectio NCT02076100 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Pa NCT01804829 | Biotest Pharmaceuticals Corporation | Phase 3 |
| Terminated | Interaction Between Paroxetine and Telaprevir NCT01841502 | Radboud University Medical Center | Phase 2 |
| Withdrawn | Boceprevir in End Stage Renal Disease (ESRD) NCT02112630 | Columbia University | N/A |
| Completed | A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infectio NCT01803308 | Syneos Health | Phase 1 |
| Terminated | Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in P NCT01532908 | MassBiologics | Phase 2 |
| Terminated | Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection NCT01560468 | Schiano, Thomas D., MD | Phase 1 |
| Terminated | Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir NCT01465516 | Arrowhead Regional Medical Center | — |
| Unknown | Effects of Vitamin D on Inflammation in Liver Disease NCT01754961 | Veterans Medical Research Foundation | Phase 2 |
| Completed | Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection NCT01771653 | Southern Illinois University | — |
| Unknown | 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA a NCT01683786 | Chang Gung Memorial Hospital | Phase 4 |
| Completed | Study on Immunopathogenesis in HIV and Hepatitis C Coinfection NCT01296529 | Rush University Medical Center | — |
| Completed | Study of a New MVA Vaccine for Hepatitis C Virus NCT01296451 | ReiThera Srl | Phase 1 |
| Completed | Study of SCY-635, Pegasys and Copegus in Hepatitis C NCT01265511 | Scynexis, Inc. | Phase 2 |
| Completed | A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures NCT01185028 | National Institutes of Health Clinical Center (CC) | Phase 1 / Phase 2 |
| Terminated | Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia NCT01153919 | University of Southern California | Phase 2 |
| Completed | An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject NCT01051414 | Bristol-Myers Squibb | Phase 2 |
| Completed | Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected NCT00991289 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interfer NCT01017575 | Bristol-Myers Squibb | Phase 2 |
| Completed | Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribav NCT01016912 | Bristol-Myers Squibb | Phase 2 |
| Completed | Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribaviri NCT00874770 | Bristol-Myers Squibb | Phase 2 |
| Completed | Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection NCT00513461 | Chao Family Comprehensive Cancer Center | Phase 2 |
| Completed | An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users NCT00841477 | National Institute on Drug Abuse (NIDA) | Phase 3 |